Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Opentrons, founded in 2014 and headquartered in Brooklyn, New York, is a life science company specializing in laboratory automation for research and healthcare sectors. The company provides user-friendly liquid-handling robots and genome-scale cell engineering solutions to streamline Research and Development (R&D) operations in academic, biopharma, synthetic biology, and clinical research labs.
Since its inception, Opentrons has demonstrated significant growth and attracted substantial investment. The company has raised a total of $250.83 million across multiple funding rounds, with its most recent Series C round in September 2021 securing $200 million. This funding round, led by SoftBank Vision Fund 2 and Khosla Ventures, valued the company at $1.8 billion, marking a significant milestone in Opentrons' journey.
While we have not found any specific news or reports regarding Opentrons' IPO prospects, it's important to note that the company's rapid growth and substantial funding could potentially position it for future public market considerations. However, any discussions about a potential IPO remain speculative at this point.
Several factors could influence Opentrons' decision regarding an IPO, including market conditions, the company's financial performance, and its long-term strategic goals. The robotics and laboratory automation industry continues to expand, which may present opportunities for companies like Opentrons. Additionally, the company's innovative solutions and strong investor backing could be seen as positive indicators for potential future growth.
It's crucial for investors to keep in mind that IPO decisions are complex and subject to various internal and external factors. As of now, there are no confirmed plans or official announcements regarding an Opentrons IPO. Interested parties should continue to monitor official company communications and verified financial news sources for the most up-to-date and accurate information about Opentrons' future plans.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Opentrons' IPO prospects remain uncertain, investors eager to gain exposure to innovative biotech companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the biotechnology and lab automation sectors. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry pioneers like Opentrons before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
